The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gavin Clark-Gartner - Evercore Inc - Analyst
: Hey, guys. Congrats on another great quarter. First, I just wanted to ask on LIVMARLI. What are you seeing for overall therapy persistent rates, and
has that changed at all over the last couple of years? And then on the pipeline for the ongoing VISTAS PSC trial, is there anything you're seeing on
a blinded basis that gives you increased confidence? Maybe it's blended pruritus variability tracking with expectations, baseline characteristics
continuing to come in as expected or anything else you can give us there would be really helpful thanks.
Question: Ryan Deschner - Raymond James - Analyst
: Thanks, and congrats on the quarter. Wanted to ask what main drivers are you attributing to the growth that we're seeing with LIVMARLI sales?
And then also how meaningful an impact on script volumes? Are you saying specifically due to the availability of the tablet format for LIVMARLI?
Thank you.
Question: Michael Ulz - Morgan Stanley - Analyst
: Good afternoon. Thanks for taking the question and congratulations on the quarter as well. Maybe just a question on Fragile X, sounds like you
made some nice progress interacting with the FDA on the trial design. Just curious if there's anything else you need feedback on -- or from the
FDA or any next steps before you start that study in the fourth quarter? Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 06, 2025 / 8:30PM, MIRM.OQ - Q2 2025 Mirum Pharmaceuticals Inc Earnings Call
Question: Ryan McElroy - Leerink Partners LLC - Analyst
: Hey, guys, you have Ryan on for Mani. Congrats on the quarter. Just curious how well-penetrated you guys think you are in the Alagille and PFIC
markets kind of looking at your commentary that LIVMARLI can be a $1 billion product? Wondering how you see that broken out by Alagille and
PFIC.
And then just one on the pipeline. I know Fragile X design is pretty ironed out, but are there any specific elements you're particularly interested in
from Shionogi's update later this year? Thank you.
Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst
: Thanks very much. Once I be on the expand study. I was wondering if you could share if any of those eligible patients already on the Mali through
Compassionate E or other exceptions.
Question: David Lebowitz - Citibank Cameroon SA - Analyst
: Thank you for taking my question. I know a few years ago, $500 million was you as kind of the the peak for for Marley, this is obviously a dramatic
shift. How much of it comes from potential from the new indications, versus Pic and ALGS. New potential I think so.
Question: David Lebowitz - Citibank Cameroon SA - Analyst
: Got it. Thanks for taking my question. Yeah, thanks for the question.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 06, 2025 / 8:30PM, MIRM.OQ - Q2 2025 Mirum Pharmaceuticals Inc Earnings Call
Question: Jonathan Wolleben - Citizens JMP Securities LLC - Analyst
: Hey, thanks for taking the question. Two for me. One on PC with active pruritis and wondering if there's any evidence that that's due specifically
due to excess bile acids or if there could be any other drivers of puritus in that group. And then, second one, just wondering on CTX if you guys
have seen any inflection that you can promote and what do you expect for that long term. Thanks.
Question: Swayampakula Ramakanth - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Thank you, thanks for taking my questions. I have two of them. The first one being on Marley, so you made some remarks regarding how tea is
managing the Japanese part of the the collaboration, any remarks on how you're going about in Europe. And, it also it became what sort of efforts
are you making to increase your penetration. So that's question number one on the question number two is on the, based on the expand study,
what sort of additional population patient population can you bring to live morally. Thanks.
| 
